Clinical Trial

TAS-102 Combined With Bevacizumab for Second-line Maintenance Treatment of Advanced Colorectal Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 5, 2024 (before its estimated October 15, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study is a randomized, controlled, open-label, multicentre clinical study. This study is designed to evaluate the efficacy and safety of TAS-102 combined with bevacizumab as second-line maintenance therapy versus standard chemotherapy combined with bevacizumab as second-line continuous therapy in advanced colorectal cancer after second-line induction therapy.
Trial Details
NCT Number NCT06293014
Lead Sponsor Henan Cancer Hospital
Conditions Colorectal Cancer
Enrollment 224 participants
Start Date 2024-02-23
Primary Completion 2025-10-15 (estimated)
Study Completion 2026-11-28 (estimated)
Updated on ClinicalTrials.gov 2024-03-05